Arcus Biosciences Inc. (RCUS) carries a Roarable Rating of D- (Sell) with 35/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-01, Arcus Biosciences Inc. (NYSE: RCUS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $18.61 (+1.20% 1D, market cap $2.37B). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, RCUS ranks #809 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RCUS carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, HCM (HUTCHMED (China) Limited) holds a D grade (46/100 RQD, P/E 5.2x, ROIC -2.5%, cap $2.37B) and PGEN (Precigen Inc.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $2.38B). Among the 5-stock peer group, HCM leads on earnings multiple (5.2x) while PBH leads on capital efficiency (13.8% ROIC).
Per RCUS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001724521), Arcus Biosciences Inc. generated $33.0M in revenue (-35.3% YoY), -$353.0M in net income, and -$484.0M in free cash flow against $1.14B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
20D Institutional Volume Accumulation (±12.5% realized swing band)
FRED Regime × Technicals: 8% of 52W Range • RSI-14 at 30 (OVERSOLD (<32))
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While RCUS currently carries a cautious 35/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($24.98) and Max Pain ($19.54) forces dealer call-delta covering toward $33.33.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
Arcus Biosciences Inc. (RCUS) advanced +1.20% to $18.61, trading at 8% of its 52-week range ($17.43 – $31.74). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
HAYWARD, Calif., October 26, 2026--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of can
Arcus Biosciences completed a US$250.0 million follow-on equity offering of 14,285,715 common shares at US$17.50 each, following recent casdatifan data updates in clear cell renal cell carcinoma. The equity raise signals
Arcus Biosciences has pulled back sharply in recent weeks, even though investors are still digesting fresh trial data and a sizeable equity raise. For anyone looking at the stock today, the key question is whether the cu
HAYWARD, Calif., October 22, 2026--Arcus Biosciences, Inc. (NYSE: RCUS), a late clinical-stage biopharmaceutical company focused on developing differentiated molecules and combinations for the treatment of cancer and imm
Investing.com -- Arcus Biosciences Inc (NYSE:RCUS) shares dropped 6.6% in after-hours trading Wednesday following the company's announcement of an underwritten public offering of common stock.
HAYWARD, Calif., October 21, 2026--Arcus Biosciences, Inc. (NYSE: RCUS), a late clinical-stage biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cance
Gainers Tempest Therapeutics (NASDAQ:TPST) stock rose 8.9% to $0.57 during Wednesday's after-market session. The market value of their outstanding shares is at $10.1 million. Tenax Therapeutics (NASDAQ:TENX)
CHICAGO, October 21, 2026--William Blair today announced that Alethia Young has initiated coverage of 13 biotechnology companies, marking the next step in the firm’s continued expansion of its biotech offering.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -35.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on RCUS today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for RCUS. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, Arcus Biosciences Inc. (RCUS) ranks #809 by composite RQD confidence (35/100, grade D-) and #229 by equity capitalization ($2.37B). Within this direct 5-issuer industry benchmark cohort, HCM leads on earnings valuation at 5.2x trailing P/E, while PBH leads on capital efficiency and profitability with 13.8% ROIC and 54.7% gross margin. PBH currently holds the highest overall quantitative score in the immediate peer group at 72/100 (B) compared with RCUS at 35/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| RCUS
ACTIVE
Arcus Biosciences Inc. | D- | 35/100 | — | — | -35.0% | +1.20% | $2.37B | Benchmark Subject |
| HCM HUTCHMED (China) Limited | D | 46/100 | 5.2x | — | -2.5% | +2.03% | $2.37B | /hcm-vs-rcus → |
| PGEN Precigen Inc. | D- | 35/100 | — | — | -35.0% | +9.21% | $2.38B | /pgen-vs-rcus → |
| PHVS Pharvaris N.V. | C | 63/100 | — | — | — | +2.32% | $2.34B | /phvs-vs-rcus → |
| PBH Prestige Consumer Healthcare Inc. | B | 72/100 | 12.1x | 54.7% | 13.8% | +2.01% | $2.31B | /pbh-vs-rcus → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), Arcus Biosciences Inc. (RCUS) reported GAAP revenue of $33.0M (-35.3% vs. FY2024 revenue of $51.0M , and -10.8% cumulative change since FY2023) , GAAP net income of -$353.0M, operating cash flow of -$482.0M, and free cash flow of -$484.0M (-175.0% YoY). On the balance sheet, RCUS closed FY2025 with $1.14B in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $33.0M | -$353.0M | -$482.0M | -$484.0M | $1.14B | — |
| FY2024 (FY) | 2024-12-31 | $51.0M | -$283.0M | -$170.0M | -$176.0M | $1.15B | — |
| FY2023 (FY) | 2023-12-31 | $37.0M | -$307.0M | -$306.0M | -$306.0M | — | — |
As of 2026-11-01, Arcus Biosciences Inc. (NYSE: RCUS) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 35/100 at a spot price of $18.61 (+1.20% 1D, market cap $2.37B). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, RCUS ranks #809 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), RCUS carries a Roarable D- (35/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, HCM (HUTCHMED (China) Limited) holds a D grade (46/100 RQD, P/E 5.2x, ROIC -2.5%, cap $2.37B) and PGEN (Precigen Inc.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $2.38B). Among the 5-stock peer group, HCM leads on earnings multiple (5.2x) while PBH leads on capital efficiency (13.8% ROIC).
Per RCUS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001724521), Arcus Biosciences Inc. generated $33.0M in revenue (-35.3% YoY), -$353.0M in net income, and -$484.0M in free cash flow against $1.14B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
RCUS last traded at $18.61 (+1.20% on volume of 1,665,799 shares), positioning the stock -25.50% below its 50-day simple moving average ($24.98) and -24.53% below its 200-day simple moving average ($24.66). Across its 52-week range of $17.43 to $31.74, RCUS sits at the 8.2% percentile with a 14-day RSI of 30.0 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($16.28 to $20.94).
Why RCUS Stock advanced +1.20% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Paper Trading Arena account.